Evidence map›Paper›PMID 40915424›Full record

ReviewAdvanced drug delivery reviews2025

Innovative engineering approaches to model host-microbiome interactions in vitro.

Karen M Mancera Azamar, Samanvitha Deepthi Sudi, Zahra Mohammadalizadeh, Carleigh Coffin, Ivana K Parker, Ana Maria Porras

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karen M Mancera AzamarJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Samanvitha Deepthi SudiJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Zahra MohammadalizadehJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Carleigh CoffinJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Ivana K ParkerJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States.
Ana Maria PorrasJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address: anaporras@ufl.edu.

Funding

BASIC MICROBIOLOGY &INFECTIOUS DISEASEST32AI007110 · NIAID · UNIVERSITY OF FLORIDA · PI Stephanie M Karst · 1985 to 2026
$4.3M
The Role of the Macrophage in Bacterial Vaginosis Mediated HIV RiskDP1HD115449 · NICHD · UNIVERSITY OF FLORIDA · PI Ivana Parker · 2024 to 2026
$1.6M
Microbiota and Extracellular Matrix Interactions that Drive Host Tissue RemodelingR35GM155229 · NIGMS · UNIVERSITY OF FLORIDA · PI Ana Maria Porras · 2024 to 2026
$1.1M
NIAID NIH HHS T32 AI007110NICHD NIH HHS DP1 HD115449NIGMS NIH HHS R35 GM155229
6 · The paper itself

Abstract

The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities. This scoping review examines emerging engineering approaches to design in vitro platforms that successfully integrate host and microbial components to model these interactions. Compared to traditional in vitro and in vivo approaches, these advanced microphysiological systems offer greater experimental control, human-specific biology, and reduced cost and ethical concerns. Here, we identify key challenges in the creation of these in vitro models and innovative solutions to address them by leveraging microfluidics, biomaterials, and organoid technologies, among others. These strategies have enabled the development of co-culture systems that replicate critical features of host-microbiome interfaces, including mucosal barriers, oxygen and pH gradients, mechanical stimuli, and host cell diversity. We also describe how these physiologically relevant models are uncovering new insights into epithelial-microbiota crosstalk, immune modulation by commensal microbes, and systemic effects of microbiota and their metabolites across multiple body sites. We conclude by discussing opportunities to expand these systems in scale, complexity, and clinical relevance. As these models continue to evolve, they hold the potential to transform our ability to mechanistically probe microbiome interactions, personalize therapeutic strategies, and accelerate the translation of microbiome science into clinical practice.

Indexed as

Host Microbial InteractionsMicrobiotaModels, BiologicalAnimalsCoculture TechniquesHumansOrganoidsBiomaterialsHuman-microbiome interactionsIn vitro modelsMicrobiomeMicrophysiological systemsOrgan-on-chipTissue engineering

Identifiers

PMID40915424
PMCPMC12646538

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.